Expansion in EMEA follows the business’ success with Veeva CRM
throughout North America, Latin America, and Asia Pacific
PLEASANTON, CA — April 4, 2019 — Veeva Systems (NYSE: VEEV) today announced that the Healthcare business of Merck KGaA, Darmstadt, Germany has selected Veeva CRM to improve operating efficiency and commercial effectiveness in Europe, Middle East, and Africa (EMEA). Building on the multi-year partnership with Veeva and following its success throughout North America, Latin America, and Asia Pacific, the business is now standardizing on multichannel Veeva CRM globally.
In addition to core Veeva CRM, the Healthcare business of Merck KGaA, Darmstadt, Germany is expanding use of Veeva CLM, Veeva CRM Approved Email, and Veeva CRM MyInsights across the world. These solutions will enable the business to deliver a seamless customer experience across all channels, including face-to-face, email, and web.
“Understanding our customers and delivering them the right information at the right time through the right channel is key to our commercial strategy,” said Chetak Buaria, global head of commercial excellence of the Healthcare business at Merck KGaA, Darmstadt, Germany. “We are unifying on a single global CRM solution to deliver on this vision with Veeva as our trusted global partner.”
“Veeva is committed to helping life sciences companies drive effective engagement with healthcare professionals,” said Paul Shawah, senior vice president of Veeva Commercial Cloud. “We are proud to team with the Healthcare business of Merck KGaA, Darmstadt, Germany on their important mission to bring innovative medicines to market.”
Join more than 1,700 life sciences professionals and experts at the upcoming Veeva Commercial & Medical Summit, May 13-15, in Philadelphia, PA. The event is open to Veeva customers and invited guests. Register and view the agenda at veeva.com/Summit.
For more on Veeva Vault CRM Suite, visit: veeva.com/CRM-suite
Connect with Veeva on LinkedIn: www.linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: www.twitter.com/veevasystems
Like Veeva on Facebook: www.facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.